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ROLE OF MACROPHAGES IN ADAPTIVE RESISTANCE TO ANTI-VEGF 
THERAPY 
 
Heather J. Dalton, M.D. 
Advisory Professor:  Anil K. Sood, M.D. 
Background:  The clinical implementation of therapies targeting the VEGF pathway 
in cancer has been limited by acquired resistance; yet, the mechanisms by which 
this occurs is unclear.  We investigated the role of macrophages in the development 
of acquired resistance to anti-VEGF antibody (AVA) therapy.   
Materials and Methods:  We first established a murine ovarian cancer model of 
resistance to anti-VEGF therapy.  Using this model we investigated changes in 
macrophage infiltration during AVA sensitive and resistant phases.  We also 
investigated the in vivo effects of macrophage depletion at the emergence of anti-
VEGF resistance and in upfront combination with AVA therapy.  In vitro, we 
assessed differences in viability and invasion/migration in AVA sensitive and 
resistant macrophages.  We also investigated macrophage VEGF receptor 
expression in response to AVA therapy.  Finally, we performed high throughput 
analyses to determine pathways important in modulating macrophage response to 
AVA. 
Results:  We show that macrophages are actively recruited to the tumor 
microenvironment, where their accumulation correlates with the emergence of anti-
VEGF resistance. Importantly, depletion of macrophages at the emergence of anti-
VEGF resistance halts tumor growth and significantly prolongs survival in murine 
models.  Additionally, the upfront combination of anti-VEGF therapy with 
macrophage depletion is synergistic, decreasing tumor growth in vivo.  We found 
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downregulation of macrophage VEGFR-1 expression in conjunction with 
upregulation of alternative angiogenic and anti-apoptotic pathways at the 
emergence of resistance, possibly facilitating escape from VEGF-directed therapies.   
Conclusions:  After establishing murine ovarian cancer models of anti-VEGF 
resistance, we demonstrate a previously unrecognized role for macrophages in 
adaptive resistance to anti-VEGF therapy.  Depletion of macrophages restores 
sensitivity to AVA therapy and reduces tumor growth in combination with VEGF 
blockade.  Collectively, this study highlights macrophages as catalysts in the 
development of anti-VEGF resistance and offers strategies to modulate the 
influence of macrophages, thus improving the effectiveness of anti-VEGF therapy. 
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Background and Introduction 
Epithelial ovarian cancer 
In 2014, an estimated 14,270 new cases of epithelial ovarian cancer will be 
diagnosed, while approximately 21,980 women will die of this disease, making it the 
fifth leading cause of cancer death among women and the most lethal gynecological 
malignancy (1). Improvements in surgical approaches and the utilization of platinum 
and taxane-based cytotoxic agents has resulted in a 1.6 year gain in life expectancy 
over the last thirty years (2, 3).  Despite these improvements and an initial response 
to chemotherapy in up to 80% of patients  with advanced disease, the majority of 
these women will relapse after first-line treatment and eventually succumb to their 
disease (4, 5).  
Treatment options following recurrence often depend on the elapsed interval 
from when the patient last received platinum-based therapy.  In patients with 
platinum-resistant disease (i.e., cancer recurrence or progression within 6 months 
after receiving platinum therapy), single-agent chemotherapy is most commonly 
recommended. Such agents include docetaxel, topotecan, pegylated liposomal 
doxorubicin, gemcitabine, or weekly paclitaxel (6). Response to these second-line 
treatments has yielded disappointing results of approximately 20% (7-10).   
  These findings highlight the need for more efficacious chemotherapy 
regimens in both the up-front and recurrent settings. Increasingly, attention has 
been focused on targeting the biological pathways that fuel ovarian cancer growth. 
One attractive strategy is directed at targeting tumor blood vessel growth, a process 
known as anti-angiogenesis therapy (6).  
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Angiogenesis and tumor growth 
Angiogenesis is a central hallmark of cancer  and is essential for tumor 
growth and metastasis (11). While the mechanisms regulating blood vessel 
formation in cancer are complex, the vascular endothelial growth factor (VEGF) 
family is known to be a predominate pathway (12). VEGF (VEGF-A) interacts with 
the tyrosine receptor kinase, VEGF Receptor-2 (VEGFR-2), and is the central 
promoter of tumor angiogenesis (13, 14).  VEGF also has known angiocrine and 
intracrine functions, where it has been shown to modulate cancer cell survival (15, 
16).  Cofactors Neuropilin 1 and 2 (NRP1, NRP2), potentiate the activity of VEGFR-
2 and can also signal independently. VEGF can exist as both soluble and matrix-
bound isoforms, with the former controlling vessel enlargement and the later 
regulating branching morphogenesis (17). 
VEGF-C is another member of the VEGF family capable of interaction with 
both VEGFR-2 and VEGFR-3.  VEGF-C regulates the activation of blood vessel tip 
cells (18). VEGFR-3 is essential for blood vessel formation during embryogenesis 
and later plays important roles in the regulation of lymphangiogenesis (19). 
Importantly, VEGFR-3 can augment VEGF-induced angiogenesis and sustains 
blood vessel growth, even in the presence of VEGFR-2 inhibitors (19).  
VEGF Receptor-1 (VEGFR-1) interacts with VEGF-B and also binds to VEGF 
with high affinity.  VEGFR-1 may serve as an alternative receptor for VEGF, thereby 
regulating the amount of VEGF available to activate VEGFR-2.  In support of this 
concept, loss of VEGFR-1 results in vessel overgrowth (20). VEGFR-1 also plays 
roles in the pathologic angiogenesis seen in tumor growth. Tumor cells are known 
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to express VEGFR-1, which may facilitate VEGF interaction through autocrine 
mechanisms (21). Additionally, VEGFR-1 is capable of inducing the growth of 
VEGFR-1-expressing tumor cells (22). 
Placental growth factor (PlGF) is another member of the VEGF family, acting 
as a cytokine to stimulate angiogenesis.  PlGF activates bone-marrow derived 
myeloid cells and endothelial progenitors, in addition to directly activating tumor 
cells (20).  PlGF can also directly bind to VEGFR-1 (17). 
In addition to the VEGF family, other factors make substantial contributions 
to aberrant angiogenesis, including the notch-deltalike ligand 4 (Dll4) pathway.  
Vascular endothelial cells express the notch 1 and 4 receptors, as well as the 
ligands jagged 1, Dll1, and Dll4.  This pathway has also been implicated in the 
establishment of a perivascular niche for colon cancer stem cells by endothelial 
cells (23). Notch-Dll4 signaling is critical for embryonic angiogenesis, as its 
haploinsufficiency in knock-out experiments is lethal (24).  Dll4 is upreglated in 
tumor vasculature, in part by VEGF, which may allow it to serve as a negative 
feedback mechanism for sustained angiogenesis (25). 
The angiopoietin-Tie pathway also plays roles in tumor angiogenesis. Tie-1 
and Tie-2 are tyrosine kinases predominantly found on vascular endothelium and 
serve as receptors for the ligands, ANG-1, ANG-2, and ANG-4.  ANG-1 works 
through Tie-2 to regulate endothelial cell quiescence and vessel tightness (26).  In 
response to angiogenic stimuli, sprouting endothelial cells release ANG-2, which 
antagonizes the activity of ANG-1 and Tie-2 and increases vascular permeability 
and vessel sprouting (27).  In cooperation with VEGF, ANG-2 works to stabilize and 
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mature new capillaries (25). ANG-2 is also released by tumor cells, resulting in the 
recruitment of pro-angiogenic Tie-2 expressing monocytes and macrophages (28). 
Therapies targeting angiogenic pathways in cancer 
Given the importance of angiogenesis in tumor growth, therapies targeting 
VEGF and other pro-angiogenic pathways have been the subject of intense 
investigation. The first targeted anti-angiogenic agent was approved by the Food 
and Drug Administration (FDA) in 2004.  Bevacizumab, a humanized monoclonal 
VEGF antibody, demonstrated activity in metastatic colorectal cancer in 
combination with standard chemotherapy, resulting in a survival benefit in a 
randomized phase 3 trial (29).  Bevacizumab was subsequently approved by the 
FDA for the treatment of advanced non-small cell lung cancer, renal cell carcinoma, 
and recurrent glioblastoma (30). This agent was also initially approved for the 
treatment of metastatic breast cancer; however, this approval was withdrawn in 
2011 after failing to improve overall survival.  Bevacizumab has also been use in 
both the up-front and recurrent ovarian cancer settings, with improvement in 
progression-free survival, which may be reasonable endpoint given the prolonged 
survival of these patients following progression (31). In the setting of recurrent 
disease, historical response rates to bevacizumab as monotherapy range from 16% 
to 21%.  Combination with other chemotherapeutic agents increases response rates 
to 24-31% (32).   
Several small-molecule receptor-tyrosine-kinase inhibitors (RKTIs) have 
been approved as targeted anti-angiogenic agents. Sunitinib targets multiple 
tyrosine kinases, including VEGFR-1, VEGFR-2, Platelet-derived growth factor 
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receptors (PDGFRs), and macrophage colony stimulating factor receptor (CSF1R), 
with demonstrated activity in pancreatic neuroendocrine tumors, advanced renal cell 
carcinoma, and gastrointestinal stromal tumors (25, 33). Sorafenib is FDA-approved 
for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer 
and inhibits VEGFR-1, VEGFR-2, and VEGFR-3, as well as PDGFR-β (34).  
Alternative methods to target VEGF include aflibercept, a fusion protein composed 
of the VEGFR-1 and VEGFR-2 extracellular domains with high affinity for VEGF-A, 
VEGF-B, and PlGF(30).  Compounds directed at the ANG-TIE pathway are also in 
developm
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These graphs show a 30 year period of ovarian cancer incidence and mortality.  On left you can see a 
slight decrease in the overall incidence of ovarian cancer.  Improvements in surgical approaches and the 
utilization of platinum and taxane-based cytotoxic agents has resulted in a 1.6 year gain in life 
expectancy over the last thirty years. Despite these improvements and an initial response to 
chemotherapy in up to 80% of patients with advanced disease, the majority of these women will relapse 
after first-line treatment and eventually succumb to their disease.  Thus there is a continued impetus for 
new treatment options, including the development of targeted agents. 
Angiogenesis is a central hallmark of cancer and is essential for tumor growth and metastasis. While the 
mechanisms regulating blood vessel formation in cancer are complex, the vascular endothelial growth 
factor (VEGF) family has been found to be a predominate pathway.  This Family of glycoproteins and 
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Bevacizumab, a humanized monoclonal VEGF antibody, demonstrated activity in metastatic 
colorectal cancer in combination with standard chemotherapy, resulting in a survival benefit in a 
randomized phase 3 trial.  Bevacizumab was subsequently approved by the FDA for the 
treatment of advanced non-small cell lung cancer, renal cell carcinoma, and recurrent 
glioblastoma. This agent was also initially approved for the treatment of metastatic breast 
cancer; however, this approval was withdrawn in 2011 after failing to improve overall survival.  
Bevacizumab has also been use in both the up-front and recurrent ovarian cancer settings, with 
improvement in progression-free survival 
Several small-molecule receptor-tyrosine-kinase inhibitors (RKTIs) have been approved as 
targeted anti-angiogenic agents. Sunitinib targets multiple tyrosine kinases, including VEGFR-1, 
VEGFR-2, Platelet-derived growth factor receptors (PDGFRs), and macrophage colony 
stimulating factor receptor (CSF1R), with demonstrated activity in pancreatic neuroendocrine 
tumors, advanced renal cell carcinoma, and gastrointestinal stromal tumors (25, 33). Sorafenib 
is FDA-approved for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid 
cancer and inhibits VEGFR-1, VEGFR-2, and VEGFR-3, as well as PDGFR-b (34).  Alternative 
methods to target VEGF include aflibercept, a fusion protein composed of the VEGFR-1 and 
VEGFR-2 extracellular domains with high affinity for VEGF-A, VEGF-B, and PlGF(30) 
 
As angiogenesis is a critical component for tumor growth and VEGF is constitutively overexpressed in 
numerous cancers, therapies targeting this pathway were eagerly anticipated additions to standard 
ent.   
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In ovarian cancer, numerous agents targeting angiogenesis are being 
investigated.  AMG 386 is an inhibitor of ANG-1 and ANG-2 with activity in recurrent 
ovarian cancer currently in clinical trials. Others include the multi-kinase inhibitor, 
cediranib, which targets VEGFR-1, -2, and -3, PDGFR-α/β, FGFR-1, and c-kit; 
and nintedanib, directed against VEGFR-1, -2, and -3, PDGFR-α/β, FGFR-1, -2, 
and -3, as well as the sarcoma viral oncogene homolog (Src) family.  Pazopanib, 
targeting VEGFR-1, -2, and -3, PDGFR-α/β, FGFR-1 and -3, and c-kit; and 
sorafenib are also being evaluated (5). 
Adaptive resistance to anti-angiogenic therapies 
As angiogenesis is a critical component for tumor growth and VEGF is constitutively 
overexpressed in numerous cancers, therapies targeting this pathway were eagerly 
anticipated additions to standard chemotherapy (35, 36). Yet, clinical survival 
benefits have been modest, usually measured in months (25).  Resistance to 
angiogenic blockade often develops (17). Rebound tumor growth, along with rapid 
revascularization following termination of anti-angiogenic therapies, has been 
demonstrated (37, 38).  Intriguingly, collapse of survival curves and clinical benefit 
is observed following cessation of agents such as bevacizumab (39-41). Several 
mechanisms for this phenomenon have been proposed.  VEGF blockade produces 
hypoxia at the tumor level, which can increase the production of alternative pro-
angiogenic factors. Tumors may also utilize other methods of vascularization, such 
as vasculogenic mimicry or vessel co-option. Further, stromal components of the 
tumor microenvironment, including macrophages, may offer alternative angiogenic 
avenues in the setting of VEGF blockade (17).  T-helper type 17 cells, with their 
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major cytokine IL-17, have been implicated in such mechanisms of resistance to 
anti-VEGF therapy through induction of G-CSF and recruitment of immature 
myeloid cells, including macrophages (42) 
Characterization of Macrophages 
Macrophages arise from differentiated monocytes, which enter the circulation after 
development from a myeloid progenitor in the bone-marrow.  The transcriptome of 
macrophages is complex, allowing them to serve diverse and often tissue-specific 
functions (43). Historically, macrophages have been described as classically 
activated M1 or alternatively activated M2 phenotypes. These phenotypes are now 
thought to represent extremes in a continuum of macrophage activation, and have 
been reversed, highlighting their plasticity in response to environmental signals (44-
46). 
Pro-inflammatory macrophages, or the classical M1 phenotype, react to  
STAT1 signaling pathways through response to INF-γ and activation of Toll-like 
receptors (TLRs) (47). TNFα, IL-1β, IL-6, IL-12, type 1 INF, as well as reactive 
oxygen species contribute to the pro-inflammatory properties of this phenotype 
(Table 1) (48). Arginine metabolism leads to inducible nitric oxide production. Major 
histocompatibility complex II (MHC II) is elevated, allowing interactions with Th1 
cells (49).  STAT3 and STAT6 are activated by IL-4 and IL-13, with subsequent 
transcription of characteristic genes of pro-angiogenic macrophages,  (50). The 
arginase pathway results in the production of ornithine and polyamines (51). 
Characteristic features are seen in Table 1.  
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Table 1.  Associated chemokines and cytokines of macrophage phenotypes. 
 Pro-inflammatory 
Macrophages 
Pro-angiogenic 
Macrophages 
Cytokines and 
Chemokines 
CCL3, CCL4, CCL5, 
CCL8, CXCL9, CXCL10, 
CXCL11 
CCL2, CCL16, CCL17, 
CCL18, CCL22, CCL24, 
CXCL1, CXCL2 
Other factors 
TNF-α, IL-1β, IL-6, IL-12, 
INF, Reactive O2 species 
MMPs, IL-8, VEGF-A, 
VEGF-C, VEGF-D, FGF-
2, ARG-1, Wnt5a, Wnt7b 
Surface Receptors 
CCR7, CD14, CD16, 
CD32, CD64, CD84, 
CD86, MHCII, 
TRL2/TRL4, CSF1-R 
CD14, CD23, CD163, 
CXCR1, CXCR2, CXCR4, 
CCR2, IL-1Ra, VEGFR-1, 
VEGFR-2, VEGFR-3,  
Tie-2, mannose receptor 
 
Macrophages in tumor angiogenesis 
Tumor associated macrophages (TAMs) are abundant in established tumors, 
where they were initially thought to be tumoricidal. Contemporary evidence, 
however, demonstrates a much more sinister purpose. Macrophage infiltration is 
associated with increased tumor invasion, migration and poor clinical prognosis in 
80% of solid tumors (46, 52). Tumor and stromal cells produce numerous factors 
that actively recruit macrophages to the microenvironment, including VEGF (47, 53). 
Tumors are also rich in hypoxia, a known macrophage chemoattractant. While most 
macrophages influxing into the cancerous microenvironment are believed to 
originate from the circulating monocyte population and are, therefore, bone-marrow 
derived, recent studies demonstrate the ability of resident tissue macrophages to 
proliferate.  Proliferation of resident tissue macrophages has been described as the 
dominant mechanism for the establishment of peritoneal macrophages in the 
postnatal period. Specifically, in the context of inflammation, both resident 
peritoneal macrophages and recruited bone-marrow derived macrophages have 
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been demonstrated to proliferate in the microenvironment, adding new complexity 
our previous understandings of macrophage differentiation (54). This proliferative 
ability has recently been linked to the transcription factor Gata6 (55). 
 Once in the tumor microenvironment, macrophages secrete numerous pro-
angiogenic factors including VEGF-A, VEGF-C, VEGF-D, IL-8, and FGF-2; which 
help flip the angiogenic switch regulating the transformation to malignancy (21, 46, 
56). Increased capillary density is correlated with TAM infiltration (21).  
Macrophages also express VEGFR-1, VEGFR-2, and VEGFR-3, permitting 
interaction with ligands of the VEGF family (56, 57). TAMs are transcriptionally 
similar to the pro-angiogenic macrophage phenotype, with high levels of IL-8, TGF-
β, ARG-1 and the mannose receptor in conjunction with low levels of pro-
inflammatory cytokines (53, 58).  In response to hypoxia, macrophages upregulate 
HIF-1α and HIF-2α, which facilitate the transcription of genes involved in 
angiogenesis (53).  Tie2 is also upregulated, enhancing pro-angiogenic polarization. 
Response to anti-cancer therapies can be altered by TAMs. Radiotherapy 
induces CSF1, leading to recruitment of CSF1R-expressing macrophages and 
enhanced tumor regrowth via their associated pro-angiogenic properties, while 
CSF1R inhibitors have resulted in improved response to radiation (59). Tumor 
regrowth following radiotherapy is linked to macrophage recruitment by CXL12 in 
response to hypoxia.  Platinum therapy increases pro-angiogenic macrophages in 
tumor samples (60). Further, macrophages are associated with the development of 
resistance to anti-tumor therapies, including platinum-based chemotherapy and 
radiotherapy (59-61). The development of resistance to anti-VEGF therapy has 
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been linked to macrophages, secondary to their ability to activate pro-angiogenic 
pathways (62). Macrophages are also directly tied to vascular regrowth following 
therapy-induced vascular injury (61).  
Mechanisms to target macrophages 
Numerous methods of targeting macrophage-driven angiogenesis are 
currently being investigated. Bisphosphonates, used clinically for the treatment of 
osteoporosis and bony metastases, are one potential approach. Multiple large-scale 
studies have demonstrated the reduced risk of breast and colon cancers in patients 
receiving bisphosphonates (46, 63).  Bisphosphonates  reduce bone metastasis in 
breast cancer patients, and in those with prostate or renal cell carcinoma and pre-
existing bone metastasis, result in a trend towards increased survival (64).  
Bisphosphonates work by inhibiting of osteoclast activity, which contributes to the 
growth of solid tumors by liberating bone marrow-derived growth factors such as 
TGF-β and IGF. Importantly, they also have been found to directly induce apoptosis 
in TAMS with a resultant decrease in tumor infiltration and associated pro-
angiogenic factors that aid tumor growth and spread. This apoptotic effect is 
mediated through the inhibition of farnesyl diphosphate synthase, which prevents 
prenylation of small GTPase signaling proteins required for normal cellular function 
(65). Bisphosphonate treatment has also significantly reduced angiogenesis in 
several murine cancer models (66).   
The DNA binding agent, trabectedin, has activity against macrophages. 
Treatment with trabectedin reduced TAM infiltration, resulting in significantly 
reduced tumor growth and metastasis, as well as decreased angiogenesis (67). 
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These effects are mediated through induction of the extrinsic apoptosis pathway, 
with specificity for cells of monocytic lineage.  The expression of functional TRAIL 
receptors seen on monocytes and TAMs is responsible for this specificity, as 
neutrophils and lymphocytes have decoy TRAIL receptors, which impart protection 
from the effects of trabectedin (67). 
Inhibition of the CSF1 receptor (CSF1R) is also being investigated, as its 
ligand, CSF1, is a potent recruiter of macrophages and monocytes and is 
unregulated in the tumor microenvironment. In prostate cancer models, the CSF1R 
inhibitor, GW2580, reduced tumor regrowth following irradiation and reduced 
infiltration of TAMs (68). This selective small kinase inhibitor competitively binds to 
CSF1R, thereby preventing CSF-1-dependent macrophage growth (69).  Reduced 
TAM recruitment and decreased vascular density was seen in breast cancer 
models, along with reduced tumor growth in prostate cancer models following 
treatment with the small molecule CSF1R kinase inhibitor, PLX3397. Additionally, 
treatment with PLX3397 enhanced CD8+ T cell response, resulting in improved 
chemosensitivity (70). AC708 is another high-affinity CSF1R inhibitor with 
demonstrated activity in breast cancer models currently in clinical development 
(work yet unpublished, poster presented at AACR 2013). 
PF-04136309, a CCR2 inhibitor, depletes TAMs, reduces metastasis, and 
enhances chemosensitivity in pancreatic cancer models (71). Anti-STAT3 agents 
offer additional possibilities for macrophage modulation (71).  Anti-Ang2 antibodies 
produced regression of tumor vasculature and decreased tumor progression in 
murine models of pancreatic and breast cancer (62).   
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Macrophage reprogramming is being explored through the PD-1 
(programmed death-1) pathway. This inhibitory factor is secreted by macrophages 
in the tumor microenvironment, with a subsequent reduction in CD8+ cytotoxic T cell 
activity and induced immune tolerance. In an ovarian cancer model, PD-L1 
blockade, in combination with whole tumor antigen vaccination, increased immune 
activity and facilitated tumor rejection through stimulation of CD8+ T cells (46, 72). 
This tumoricidal macrophage phenotype is achieved through administration of an 
agonistic CD40 antibody for “priming,” followed by a “triggering” signal mediated 
through toll-like receptors (TLRs). This method of macrophage reprogramming  has 
produced tumor regression in vivo (73). 
Tumor cells express “don’t eat me” signals through expression of CD47.  
This surface receptor interacts with signal regulatory protein α (SIRPα) on the 
surface of TAMs, inducing a powerful anti-phagocytosis signal. CD47 inhibition 
increases the phagocytic capability of macrophages with resultant tumoricidal 
response.  These anti-CD47 antibody therapies are currently in clinical development 
(73). 
Macrophage-derived exosomes are also being utilized to achieve targeted 
drug delivery to the tumor microenvironment. These endogenous nanovesicles are 
capable of transferring biological information between cells. Recently, macrophages 
have been broken down into nanovesicles mimicking exosomes, with retention of 
plasma membrane proteins, thus maintaining the inherent targeting ability of the 
original macrophage. These macrophage-derived nanovesicles have been loaded 
with various chemotherapeutic agents and demonstrated to track to the tumor 
14 
 
microenvironment in vivo, resulting in decreased tumor growth without the adverse 
effects associated with administration of free drug (74). 
The ability of macrophages to directly affect angiogenesis prompted us to 
specifically consider the role of macrophages in adaptive resistance to VEGF 
blockade. Given the clinical significance of adaptive resistance to anti-VEGF 
therapy, the biological roles and underlying mechanisms by which macrophages 
contribute to adaptive resistance to anti-VEGF therapy are the focus of the present 
study.  
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Hypotheses and Specific Aims 
The overall hypotheses of this project are:   
1)  Depletion of macrophages in the tumor microenvironment will alter adaptive 
tumor responses and improve the efficacy of anti-VEGF therapy. 
2)  Prolonged exposure to anti-VEGF therapy results in down-regulation of VEGF 
receptors on macrophages, allowing them to persist in the microenvironment and 
aid tumor growth through the release of pro-angiogenic factors. 
 
These hypotheses can by pictorially unified into a central hypothesis, seen in Figure 
1. Tumors are initially responsive to anti-VEGF therapy, where treatment is 
associated with a reduction both macrophage infiltration and tumor growth.  With 
prolonged treatment and the development of resistance, macrophage infiltration 
increases, with a reduction in VEGFR expression.  During this phase, tumor growth 
rapidly increases through the liberation of other macrophage-derived pro-angiogenic 
factors.  The following specific aims will test this hypothesis: 
Specific Aim 1: To determine the biological role of macrophages in adaptive 
resistance to anti-VEGF therapy 
Specific Aim 2: To identify the mechanisms by which macrophages 
contribute to adaptive resistance to anti-VEGF therapy. 
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Figure 1. Central Hypothesis.  VEGFR-expressing (green) and VEGFR-negative 
(red) macrophages are found in the tumor microenvironment.  The initiation of anti-
VEGF therapy reduces both tumor size and macrophage infiltration.  In this phase, 
macrophages expressing VEGFR predominate.  With continued anti-VEGF therapy, 
resistance emerges and VEGFR-negative macrophages are found in abundance in 
the microenvironment. 
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Methods 
Cell lines and tissue culture 
IG10 cells were maintained in DMEM-F12 supplemented with 5% fetal 
bovine serum, 1x insulin-transferrin-sodium selenite supplement (Roche 
Diagnostics, Indianapolis, IN), and 0.1% gentamicin sulfate (Gemini Bioproducts, 
Calabasas, CA). OVCAR5 was maintained in DMEM with 10% fetal bovine serum, 
and 0.1% gentamicin sulfate. SKOV3ip1 was maintained in RPMI 1640 
supplemented with 15% fetal bovine serum and 0.1% gentamicin sulfate. All cell 
lines were routinely screened for mycoplasma and experiments were performed at 
60-80% cell confluence. 
Immortomouse macrophages 
Immortomouse macrophages, a kind gift from Dr. Robert Langley, were 
maintained in DMEM with 10% fetal bovine serum, and 0.1% gentamicin sulfate.  
These conditionally immortalized cells are derived from the immortomouse (Jackson 
Laboratory, Bar Harbor, ME)  and bear a transgene which allows interferon-
inducible expression of a thermolabile large tumor antigen (TAg) (and the small 
tumor antigen) from the SV40 thermosensitive A58 (tsA58) strain directed to 
widespread tissues by the interferon-inducible Class I antigen promoter from the 
mouse H-2Kb locus. The tsA58 TAg gene product is functional at the 33°C, but is 
rapidly degraded at 39.5°C (75). In this way, immortomouse macrophages could be 
cultured at 33°C, where they proliferate as an immortalized cell line, but fail to 
proliferate after incubation at 39.5°C. 
Animal studies  
18 
 
All animal work was done in accordance with protocols approved by the MD 
Anderson Institutional Animal Care and Use Committee.  Female athymic nude 
mice and immune competent (C57BL/6) mice were purchased from the Animal 
Production Area of the National Cancer Institute-Frederick Cancer Research and 
Development Center (Frederick, MD). All animals were cared for in accordance to 
the guidelines set forth by the American Association for Accreditation of Laboratory 
Animal Care and the US Public Health Service policy on Human Care and Use. All 
animals used were 8-12 weeks old at the time of injection.  
In vivo model of ovarian cancer and tissue processing 
For all animal experiments, cells were harvested using trypsin-EDTA, 
neutralized with FBS-containing media, washed, and re-suspended to the 
appropriate cell number in HBSS prior to injection. IG10 (1x106) cells were 
transduced with lentivirus-encoding luciferase and injected into C57BL/6 mice. Mice 
were imaged once weekly for luminescent signals using a Xenogen IVIS system. 
For syngeneic experiments, B20 mAb, a murine monoclonal VEGF-A and VEGFR-2 
antibody (Genentech Inc, San Francisco, CA) was administered intraperitoneally at 
5mg/kg, twice weekly. For nude models, bevacizumab was given intraperitoneally at 
6.25 mg/kg, twice per week. Zoledronic acid was given intraperitoneally at 1 mg/kg, 
once weekly. At the time of necropsy, the weight, number, and distribution of tumors 
were recorded. Individuals who performed necropsies were blinded to the treatment 
group assignments. Tissue specimens were fixed with either formalin or optimal 
cutting temperature compound (OCT) (Miles, Elkhart, IN), or snap frozen in liquid 
nitrogen.  
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Quantitative real-time PCR  
The total RNA from either cell lines or tumor tissue was extracted using a 
Qiagen RNeasy Kit (Qiagen, Valencia, CA). Using 1 µg of RNA, cDNA was 
synthesized using a Verso cDNA kit (Thermo Scientific, Houston, TX) per the 
manufacturer's instructions. cDNA was then subjected to amplification by real-time 
PCR using specific primer sequences (100 ng/µL) as specified in Table 2. For real-
time RT-PCR, we obtained quantitative values (each sample was normalized on the 
basis of its 18S content) as previously described (76).  
Table 2. PCR primer sequences. 
Gene Forward Sequence Reverse Sequence 
VEGFR1 5’-CGGAAGGAAGACAGCTCATC-3’ 5’-CTTCACGCGACAGGTGTAGA-3’ 
VEGFR3 5’-CCCCGGTGTCAATCACATA-3’ 5’-CTCTGCCTCGGACTCCTC-3’ 
 
Methylation-specific PCR 
MethPrimer software (http://www.urogene.org/methprimer/) was used for the 
prediction of the CpG islands of the murine VEGFR1 promoter regions and for 
design of methylation-specific primers.  CpG islands of the promoter are seen in   
Figure 2.  
Figure 2.  VEGFR-1 promoter CpG islands.  VEGFR-1 promoter CpG islands are 
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shown above, as predicted using MethPrimer software.  Actual CpG sequences are 
shown along the bottom as red dashes. 
Using this software, appropriate primers were designed (VEGFR1 
methylated sense: 5’- GGAGTTTGTAAGGATTTTTTGAGC-3’, VEGFR1 methylated 
antisense: 5’- CGACACCTCCTTCTAATAACGTC-3’, VEGFR1 un-methylated 
sense: 5’- GGAGTTTGTAAGGATTTTTTGAGTG-3’, VEGFR1 un-methylated 
antisense: 5’- CCAACACCTCCTTCTAATAACATC-3’. Total DNA was isolated from 
control, AVA sensitive, and AVA resistant immortomouse macrophages cells using 
Phenol:Chloroform extraction, followed by treatment with bisulphite using a 
methylation kit (EZ DNA Methylation-Gold; Zymo Research, Orange, CA). Using 
real-time PCR, as described above, quantification of methylation in AVA resistant 
samples was compared to AVA sensitive samples. 
Immunoblotting 
 For immunoblotting, lysates from cultured cells were prepared using modified 
RIPA buffer (50 mM Tris–HCl [pH 7.4], 150 mM NaCl, 1% Triton, 0.5% 
deoxycholate) plus 25 µg/mL leupeptin, 10 µg/mL aprotinin, 2 mM EDTA, and 1 mM 
sodium orthovana.  Protein concentrations were determined using a BCA Protein 
Assay Reagent kit (Pierce Biotechnology, Rockford, IL). Lysates were loaded and 
separated on 8% sodium dodecyl sulfate—polyacrylamide gels. Proteins were 
transferred to a nitrocellulose membrane by semidry electrophoresis (Bio-Rad 
Laboratories, Hercules, CA) overnight, blocked with 5% milk for 1 hour and then 
incubated at 4°C with primary antibody overnight. After washing with TBST, the 
membranes were incubated with horseradish peroxidase (HRP)—conjugated horse 
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anti-mouse IgG (1:2000, GE Healthcare, UK) for 2 hours. HRP was visualized by 
use of an enhanced chemiluminescence detection kit (Pierce). To confirm equal 
sample loading, the blots were probed with an antibody specific for beta-Actin (0.1 
µg/mL; Sigma). Densitometric analysis was performed using ImageJ. 
Gene Expression Microarray  
Immortalized murine macrophages were treated with AVA for 2 weeks (anti-
VEGF sensitive) and 6 weeks (anti-VEGF resistant) then RNA was extracted using 
mirVana RNA isolation labeling kit (Ambion, Grand Island, NY). Five hundred 
nanograms of total RNA were used for labeling and hybridization on a MurineWg-6 
v2 Beadchip (Illumina, San Diego, CA) according to the manufacturer’s protocol. 
After the bead chips were scanned with an Illumina BeadArray Reader (Illumina), 
the microarray data were normalized using the quantile normalization method in the 
Linear Models for Microarray Data (LIMMA) package in the R language 
environment. The expression level of each gene was transformed into a log2 base 
before further analysis. 
Reverse Phase Protein Arrays (RPPA) 
Immortalized murine macrophages were treated with AVA for 2 weeks 
(sensitive) and 6 weeks (resistant).  Cells were harvested at 80% confluence and 
lysed in modified radioimmunoprecipitation assay (RIPA) buffer (50 mmol/L Tris, 
150 mmol/L NaCl, 1% Triton X-100, 0.5% deoxycholate, 25 µg/mL leupeptin, 10 
µg/mL aprotinin, 2 mmol/L EDTA, and 1 mmol/L sodium orthovanadate). RPPA 
analysis was performed at the University of Texas, M.D. Anderson Cancer Center 
RPPA Core Facility using the methods described at the following web address: 
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http://www.mdanderson.org/education-and-research/resources-for-
professionals/scientific-resources/core-facilities-and-services/functional-proteomics-
rppa-core/index.html. Samples were probed with 161 antibodies by CSA 
amplification approach and visualized by DAB colorimetric reaction. Slides were 
scanned on a flatbed scanner to produce a 16-bit TIFF image. Spots from TIFF 
images were identified and the density was quantified by MicroVigene. Relative 
protein levels for each sample were determined by interpolation of each dilution 
curves from the "standard curve" (supercurve) of the slide (antibody). All data 
presented is in fold-change compared to the baseline (control treatment). Positive 
fold-change was calculated by dividing each linear value (>1.0) with average control 
linear value for each antibody tested, while negative fold-change (for linear values 
<1.0) was also calculated (using the following formula: [-1/linear fold-change]) as in 
log 2.0 value. 
Cytokine Assay 
Supernatant from cultured control, AVA sensitive and AVA resistant murine 
macrophages were stored at −20°C for batch analyses to measure cytokines. 
Supernatants were evaluated for cytokines/chemokines using the Milliplex MAP 
murine cytokine/chemokine panel (Millipore, MA). Cytokine levels were measured in 
50 µL of supernatant by Multiplex cytometric bead array (Multiplex) assay on a 
Luminex 100 Analyzer (Luminex Corp., Austin, Texas). The inter-variability for all 
inflammatory cytokines tested was less than 10%, indicating the highly reliability of 
the Multiplex-Luminex method of cytokine assay. 
Migration and invasion assays  
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Modified Boyden chambers (Coster, Boston, MA) were coated with 0.1% 
gelatin (migration) or extracellular matrix components (invasion). Untreated, AVA 
sensitive and AVA resistant immortomouse macrophages cells were suspended in 
100 µL of serum-free media following one hour of exposure to AVA and added into 
the upper chamber. Complete media for cells containing 10% FBS (500 µL) was 
added to the bottom chamber as a chemo-attractant. The chambers were incubated 
at 37°C in 5% CO2 for 6 hours (migration) or overnight (invasion). After incubation, 
cells were fixed, stained, and counted in 5 random fields using light microscopy at 
200x.   
Cell Viability Assay 
Immortalized murine macrophages sensitive and resistant to AVA therapy (1 
x 104 in 100 µL) were plated in a 96-well plate.  After 24 hours, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or MTT, was added to each 
well.  The plate was incubated at 37°C for 20 minutes and then absorbances were 
read at 570 nm (Ceres UV 900C; Bio-Tek Instrument Inc, Winooski, VT).   
Immunostaining 
All staining was performed in formalin-fixed, paraffin-embedded 8-µm thick 
tumor sections or OCT-embedded frozen tissue sections. Following 
deparaffinization, rehydration, and antigen retrieval or fixation, 3% H2O2 was used 
to block endogenous peroxidase activity for 10 minutes. Protein blocking of non-
specific epitopes was done using either 5% normal horse serum, 1% normal goat 
serum, or 4% fish gelatin in either PBS or TBS-T for 20 minutes.  Slides were 
incubated with primary antibody for CD68 (Santa Cruz, 1:400), VEGFR1 (AbCam, 
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1:500), CD-31 (Pharmingen, 1:800 for mouse tissue), overnight at 4 ºC. For 
immunohistochemistry, after primary antibody was washed with PBS, the 
appropriate amount of horseradish peroxidase-conjugated secondary antibody was 
added and visualized with 3,3’-diaminobenzidine chromogen and counterstained 
with Gill’s hematoxylin #3. For immunofluorescence, secondary antibody staining 
was performed with either Alexa 594 or 488 (Molecular Probes). Nuclear staining 
was performed with Hoechst 33342 (1:10,000; Molecular Probe H3570). Light field 
images were obtained using a Nikon Microphot FXA microscope and Leica DFC320 
digital camera, and immunofluorescent images were obtained using a Zeiss 
Axioplan 2 microscope and Hamamatsu ORCA-ER digital camera. To quantify 
microvessel density, we examined 5-10 random fields at 100x magnification for 
each tumor (5 tumors per group) and counted the microvessels within those fields 
as previously described (77). A vessel was defined as an open lumen with at least 
one adjacent CD31-positive cell. Multiple positive cells beside a single lumen were 
counted as one vessel. Quantification was performed by two investigators in a 
blinded fashion. For immunofluorescent quantification, VEGFR1 expression was 
determined using Photoshop by calculating the mean pixel density for each 
representative image. 
Statistical analysis 
Differences in continuous variables such as tumor weight were analyzed 
using the Mann-Whitney rank sum test.  Two-tailed P values of no more than 0.05 
were deemed statistically significant. Normally distributed continuous variables were 
compared using the student t-test.  Differences in variables that were not normally 
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distributed were compared using a nonparametric test (Mann-Whitney U test). Only 
two-tailed values are reported in this study. We considered P values less than 0.05 
to be significant. Statistical analysis of the clinical data was performed using 2-
sample t-test and Fisher’s exact test. Survival analysis was performed using 
Kaplan- Meier analysis.   
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Results 
Macrophage numbers increase with development of anti-VEGF resistance 
To evaluate the role of immune cells in the development of resistance to 
VEGF blockade, we first established a syngeneic mouse model of anti-VEGF 
resistance.  After intraperitoneal injection of luciferase-labeled IG10 ovarian cancer 
cells and following confirmation of tumor establishment with bioluminescence 
imaging, immune competent C57BL/6 mice were randomized to two treatment 
groups: 1) control and 2) Anti-VEGF antibody (AVA).  Treatment mice received AVA 
twice weekly and both groups underwent weekly bioluminescence imaging to 
monitor tumor growth. Mice receiving AVA were subsequently divided into AVA-
sensitive or AVA resistant groups based on imaging. AVA resistant mice were 
defined as those with increased tumor growth, by increased bioluminescence 
intensity in previously stable tumor burden (Figure 3).  This point marked clinical 
resistance to anti-VEGF therapy. All mice were subsequently sacrificed and tumors 
collected for immune cell profiling. 
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Figure 3.  Establishment of a model of AVA resistance.  Following injection of 
luciferase-labeled IG10 cells, AVA treatment was initiated and continued until 
increased tumor burden was demonstrated by bioluminescence imaging.   
 
Immune cells were isolated from the collected tumors of control, AVA-
sensitive, and AVA-resistant mice then subjected to FACS profiling. Compared to 
control samples, tumors from AVA-sensitive mice showed decreased macrophage 
infiltration.  In contrast, macrophages were increased in the tumors of AVA-resistant 
mice, while other immune cell populations remained unchanged (p<0.0001, Figure 
4).  
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Figure 4.  FACS myeloid cell profiling of tumor samples.  (A) Myeloid cells were 
isolated from tumor samples of control, AVA sensitive, and AVA resistant groups 
and sorted by flow-assisted cytometry according to CD11b+F4/80+ expression.  (B) 
The proportion of macrophage is expressed as a percentage of the total CD45+ 
cells.  **** indicates p<0.0001. 
 
Additionally, tumors from AVA-resistant mice showed increased vessel 
density compared to either control or AVA-sensitive tumors, as measured by CD31 
staining (p<0.001, Figure 5a, b).  The marked increase in macrophages seen in 
coordination with increased blood vessel density lead us to consider macrophages 
as potential catalysts in resistance to anti-VEGF therapy. 
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Figure 5.  CD31 Counts in AVA sensitive and resistant tumors.  Representative 
tumor sections are seen in at 200x magnification (A) with associated CD31 vessel 
density counts seen in (B). *** indicates p<0.001. 
 
Depletion of macrophages at the time of anti-VEGF resistance restores sensitivity 
As anti-VEGF resistance was associated with a significant increase in tumor 
macrophages in our model, we next investigated effects of their depletion using 
bisphosphonates at the emergence of resistance.  Bisphosphonates, such as 
zoledronic acid and clodronate, are clinically approved for the treatment of 
osteoporosis and bony metastases, but also induce macrophage depletion (78-80). 
(Figure 6) 
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Figure 6.  CD68 staining of tumor sections after treatment with zoledronic 
acid.  Representative SKOV3ip1 tumor sections of control and zoledronic acid-
treated tumors are shown following CD68+ immunohistochemical staining.  
Magnification is at 400x. *** indicates p<0.001. 
 
C57Bl/6 mice were again injected with luciferase-labeled IG10 ovarian 
cancer cells.  Following bioluminescence imaging to confirm establishment of tumor, 
mice were randomized to: 1) control; 2) AVA only; or 3) AVA plus zoledronic acid.  
Controls received placebo until becoming moribund and were then sacrificed.   In 
the AVA only group, treatment continued twice weekly until resistance developed, 
with sacrifice as mice became moribund. In the AVA or plus zoledronic acid group, 
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mice received anti-VEGF therapy alone until resistance was documented, as 
measured by an increase in previously stable disease burden by bioluminescence 
imaging.  At the emergence of resistance, weekly zoledronic acid was added to anti-
VEGF treatment (Figure 7).  
 
Figure 7.  Treatment schema of resistance model with zoledronic acid.  Mice 
received intraperitoneal injection of luciferase-labeled IG10 cells.  Twenty-one days 
later, mice were assigned to either AVA alone or AVA with the addition of zoledronic 
acid at the emergence of resistance, as demonstrated by bioluminescence imaging. 
 
 
The combined treatment was then continued until mice became moribund.  
The addition of zoledronic acid at the emergence of resistance halted tumor growth 
and significantly prolonged survival, as compared to either control or anti-VEGF 
therapy only (p<0.001, Figure 8).   
32 
 
 
Figure 8.  Overall survival following treatment with zoledronic acid.  Following 
intraperitoneal injection of luciferase-labeled IG10 cells, treatment was initiated per 
the treatment schema described and continued until mice became moribund.  *** 
indicates p<0.001.   
 
Macrophage depletion increases the effectiveness of anti-VEGF therapy 
In light of our data implicating macrophages in the development of resistance 
to VEGF blockade, we investigated the upfront combination of macrophage 
depletion with anti-VEGF therapy.  Nude mice were injected with either SKOV3ip1 
or OVCAR5 and then assigned to receive: 1) no treatment; 2) AVA only; 3) 
zoledronic acid only; or 4) AVA plus zoledronic acid.  Mice were sacrificed when any 
group became moribund and tumors were harvested.  The combination of AVA plus 
zoledronic acid dramatically reduced tumor weight and nodules in both the 
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SKOV3ip1 (p<0.0001 and p<0.05, Figure 9a) and OVCAR5 models (p<0.0001 and 
p<0.05, Figure 9b).  
  
Figure 9.  Zoledronic acid increases the effectiveness of AVA therapy.  Total 
tumor weight and number of nodules are shown in SKOV3ip1 and OVCAR5 ovarian 
cancer models following treatment with AVA, zoledronic acid, or the combination. 
**** indicates p<0.0001, * indicates p<0.05. 
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To ensure that our results were not specific to zoledronic acid, we repeated 
the experiment using an additional bisphosphonate, clodronate. Nude mice were 
injected with SKOV3ip1 and then randomly assigned to: 1) no treatment; 2) AVA 
only; 3) clodronate only; or 4) AVA plus clodronate.  Again, the combination of AVA 
plus clodronate significantly reduced tumor growth (weight p<0.0001, nodules 
p<0.01, Figure 10). 
  
Figure 10.  Clodronate increases the effectiveness of AVA therapy.  Total 
tumor weight and nodules are shown following treatment with clodronate, AVA, or 
the combination. **** indicates p<0.0001, *** indicates p<0.01. 
  
Additionally, the combination groups demonstrated significantly reduced 
macrophage numbers as compared to the other groups (zoledronic acid p<0.0001, 
clodronate p<0.001, Figure 11a-d).  This decrease in macrophage infiltration mirrors 
the results seen in anti-VEGF sensitive tumors in our initial immune profiling.  
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Figure 11.  Immunohistochemical staining of macrophages.  Macrophages from 
SKOV3ip1 tumor samples treated with either zoledronic acid (A), or clodronate (B), 
were stained for CD68+ and numbers compared between respective groups (C, D). 
Graphs represent the mean number of macrophages per 5 randomly selected 400x 
high power fields (HPF) ± SEM (A) or per 5 randomly selected 200x high power 
fields (HPF) ± SEM (C). Representative photomicrographs of macrophage density 
are shown following treatment with zoledronic acid (A) or clodronate (B). **** 
indicates p<0.0001, *** indicates p<0.001. 
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Anti-VEGF resistant macrophages display increased viability 
Given the marked differences in macrophage infiltration in the AVA sensitive 
and resistant settings, we wondered whether these observations may be reflective 
of two distinct populations of macrophages. To investigate phenotypic differences 
between AVA sensitive and resistant macrophages that might contribute to 
resistance, we compared cell viability using an MTT assay.  Following exposure to 
either two weeks (anti-VEGF sensitive) or six weeks (anti-VEGF resistant) of AVA 
treatment, macrophages were exposed to 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and cell viability was assessed. As compared to 
anti-VEGF sensitive macrophages, resistant macrophages demonstrated a 57% 
increase in cell viability (p<0.001, Figure 12). 
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Figure 12. Viability is increased in AVA resistant macrophages. MTT assays 
were performed on untreated, AVA sensitive, and AVA resistant macrophages. *** 
indicated p<0.001. 
 
Invasion/migration of anti-VEGF resistant macrophages not affected by anti-VEGF 
treatment  
On the basis of the increased macrophages seen at the emergence of 
resistance, we wondered if AVA resistant macrophages were better adapted to 
invade and migrate despite AVA therapy.  To address this question, we investigated 
differences in the ability of anti-VEGF sensitive and resistant macrophages to 
invade and migrate following exposure to an anti-VEGF agent.  Both groups were 
exposed to AVA for one hour before being plated into modified Boyden chambers.  
Migration and invasion were subsequently assessed at 6 hours and 24 hours, 
respectively. As predicted, AVA-sensitive macrophages displayed significantly 
inhibited migration following exposure to AVA (121 vs 91.4 cells per HPF, p<0.001).  
In contrast, the ability of AVA-resistant macrophages to migrate was increased by 
57% after exposure to AVA.  (p<0.001, Figure 13a).  While there was a trend 
towards decreased invasion of AVA-sensitive macrophages following exposure to 
AVA, this difference was not significant.  Invasion of AVA-resistant macrophages 
was not affected by AVA exposure (Figure 13b). 
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Figure 13.  Invasion and Migration Assays.  Control, AVA-sensitive, AVA-
resistant macrophages were exposed to AVA treatment for one hour and then 
plated into modified Boyden chambers to assess (A) migration (6 hours) and (B) 
invasion (24 hours).  Cell numbers per high power field (HPF, 200x) were then 
counted.  *** indicates p<0.001. 
 
Anti-VEGF resistant macrophages secrete alternative pro-angiogenic cytokines 
To assess phenotypic differences between anti-VEGF sensitive and resistant 
macrophages, we performed a cytokine array.  Supernatant was collected from 
murine macrophages exposed to either two weeks (AVA sensitive) or six weeks 
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(AVA resistant) of AVA treatment and evaluated for cytokines/chemokines using the 
Milliplex MAP murine cytokine/chemokine panel (Millipore, MA). Compared to anti-
VEGF sensitive macrophages, those resistant to VEGF blockade secreted 
significantly less VEGF and instead show a trend toward increased G-CSF and 
dramatically increased levels of the pro-angiogenic platelet-derived growth factor-aa 
(Figure 14). 
 
Figure 14.  Cytokine array of AVA sensitive and resistant macrophages.  
Cytokines altered are shown above.  Significant differences are indicated.  * 
indicates p<0.05, *** indicates p<0.001. 
 
High throughput analyses reveal changes in VEGFR expression 
Given the significant differences in macrophage numbers in the anti-VEGF 
sensitive and resistant settings, we sought to investigate the genotypic differences 
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in these populations.  Macrophages were cultured in vitro and treated with AVA 
twice weekly.  Based on our previous in vivo studies, macrophages were collected 
at two weeks and six weeks to reflect anti-VEGF sensitive and resistant conditions, 
respectively, and gene expression profiling was performed on isolated RNA.  
Pathway enrichment analysis revealed upregulation of pro-angiogenic pathways, 
including the molecules shown below (p<0.00007, Figure 15). 
 
Figure 15.  Pro-angiogenic genes upregulated in AVA resistant macrophages.  
Netwalker© software was used to analyze pathways up- and downregulated in AVA 
treated macrophages.  Pro-angiogenic pathways were found to be significantly 
upregulated. 
 
Concurrently, we also analyzed differences between macrophage 
populations in the anti-VEGF sensitive and resistant conditions using reverse phase 
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protein array (RPPA).  Macrophages were harvested and protein extracted following 
2 weeks (anti-VEGF sensitive) and 6 weeks (anti-VEGF resistant) of treatment with 
AVA in vitro.  Analysis revealed upregulation of anti-apoptotic pathways including 
proteins such as CAV1, CTNNB1, ESR1, AKT1, MCL1, BCL2, MDM2, MAPK8, 
BAX, GSK3B, BCL2L1, IGF1R,  and CDKN1A (Tables 3,4; Figure 16). 
Table 3. Associated functions of proteins significantly altered in RPPA 
 
 
Table 4.  Expanded table of RPPA network functions 
Functional Annotation 
Number of 
occurrences p-value Genes 
negative regulation of apoptosis 13 3.77E-14 
CAV1, CTNNB1, ESR1, AKT1, 
MCL1, BCL2, MDM2, MAPK8, 
BAX, GSK3B, BCL2L1, IGF1R, 
CDKN1A 
negative regulation of programmed 
cell death 13 4.06E-14 
CAV1, CTNNB1, ESR1, AKT1, 
MCL1, BCL2, MDM2, MAPK8, 
BAX, GSK3B, BCL2L1, IGF1R, 
CDKN1A 
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negative regulation of cell death 13 7.18E-14 
CAV1, CTNNB1, ESR1, AKT1, 
MCL1, BCL2, MDM2, MAPK8, 
BAX, GSK3B, BCL2L1, IGF1R, 
CDKN1A 
anti-apoptosis 10 9.60E-13 
CAV1, CTNNB1, ESR1, AKT1, 
MCL1, BCL2, BAX, BCL2L1, 
IGF1R, CDKN1A 
induction of apoptosis 10 6.22E-11 
MAPK1, AKT1, BCL2, ETS1, 
MAPK8, BAX, BCL2L1, DIABLO, 
CDKN2A, CDKN1A 
induction of programmed cell death 10 6.58E-11 
MAPK1, AKT1, BCL2, ETS1, 
MAPK8, BAX, BCL2L1, DIABLO, 
CDKN2A, CDKN1A 
regulation of binding 9 5.39E-10 
CAV1, MAPK1, AKT1, RB1, 
BCL2, MAPK8, BAX, GSK3B, 
CDKN2A 
transcription factor binding 9 2.54E-10 
CTNNB1, ESR1, MAPK1, RB1, 
BCL2, ETS1, GSK3B, PARP1, 
CDKN2A 
regulation of protein localization 8 4.84E-10 
CTNNB1, AKT1, RB1, BCL2, 
MAPK8, GSK3B, BCL2L1, 
CDKN2A 
cellular response to hormone stimulus 8 8.93E-09 
SHC1, PXN, ESR1, MAPK1, 
AKT1, EIF4EBP1, PARP1, 
IGF1R 
cellular response to endogenous 
stimulus 8 1.65E-08 
SHC1, PXN, ESR1, MAPK1, 
AKT1, EIF4EBP1, PARP1, 
IGF1R 
response to peptide hormone 
stimulus 8 1.57E-08 
SHC1, PXN, MAPK1, AKT1, 
EIF4EBP1, BCL2, PARP1, 
IGF1R 
induction of apoptosis by intracellular 
signals 7 1.87E-12 
AKT1, BCL2, MAPK8, BAX, 
BCL2L1, DIABLO, CDKN1A 
interphase 7 2.63E-07 AKT1, RB1, EIF4EBP1, BCL2, MDM2, CDKN2A, CDKN1A 
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Figure 16. Proteins significantly altered in AVA resistant macrophages. 
Proteins either significantly up- or downregulated are shown.  Netwalker© software 
was used to create networks of related molecules.   
 
Decreased macrophage VEGFR-1 expression with resistance to anti-VEGF therapy 
In the context of therapy directed at the VEGF pathway, we investigated 
whether VEGFR expression changes could be modulating the differences in 
behavior observed between AVA sensitive and resistant macrophages.  We 
assessed the effects of AVA therapy on macrophage VEGF receptor expression in 
vitro. Cultured macrophages were treated with AVA twice weekly. Subsequently, 
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VEGFR expression was assessed at baseline, two weeks (AVA sensitive), and six 
weeks (AVA resistant).  We found that, following an initial period of upregulation 
during the AVA sensitive phase, VEGFR-1 expression was significantly 
downregulated in the setting of AVA resistance (p<0.001, Figure 17).  Because 
VEGFR-1 expression was the most significantly altered in AVA resistant 
macrophages, we chose to focus on this receptor.   
 
Figure 17.  Macrophage VEGFR expression.  Macrophage VEGFR-1, VEGFR-2, 
and VEGFR-3 expression were assessed in untreated, AVA sensitive and AVA 
resistant macrophages.  VEGFR-1 expression was significantly altered in AVA 
resistant macrophages compared to those that were AVA sensitive. *** indicates 
p<0.001. 
VEGFR-1 protein levels from untreated, AVA sensitive, and AVA resistant 
macrophages were compared using western blot.  AVA resistant macrophages 
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demonstrated significantly less protein expression of VEGFR-1, as seen in Figure 
18.  These results were confirmed by immunofluorescent staining (Figure 19). 
 
Figure 18.  VEGFR-1 expression by Western Blot.  VEGFR-1 expression 
was compared in untreated, AVA sensitive, and AVA resistant macrophages using 
Western Blot.  β-actin served as a loading control. 
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Figure 19.  Immunofluorescent staining of macrophage VEGFR-1 expression.  
Following treatment with AVA, expression of VEGFR-1 was quantitated in sensitive 
and resistant macrophages.  Representative micrographs are shown at 400x 
magnification.   
 
In parallel, we assessed co-localization of CD68 and VEGFR-1 in AVA 
sensitive and AVA resistant tumor samples.  Again, we noted decreases in 
macrophage expression of VEGFR-1 (Figure 20) in AVA resistant tumors compared 
to AVA sensitive tumors.  
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Figure 21. Co-localization of macrophages and VEGFR-1 in tumor samples. 
Macrophage expression of VEGFR-1 was assessed in tumor samples (IG10) using 
CD68+ and VEGFR-1 antibodies in AVA sensitive (top panel) and AVA resistant 
(bottom panel) tumors. Representative photomicrographs are shown at 400x 
magnification. 
 
Downregulation of VEGFR-1 promoter with AVA resistance 
We sought to uncover the mechanism by which macrophage VEGFR-1 
downregulation occurs. Since VEGFR-1 methylation has been linked to the 
expression of VEGF and as  methylation is known to play a role in drug resistance 
and can be induced by hypoxia, we assessed methylation of the promoter region of 
VEGFR-1 following AVA treatment, a known generator of hypoxia (81-83).  DNA 
samples from AVA sensitive and resistant macrophages were treated with bisulphite 
48 
 
and methylation-specific polymerase chain reaction (MSP) analysis was performed, 
revealing a significant increase in methylation at the at the VEGFR-1 promoter 
region (p<0.05, Figure 21).   
 
Figure 21.  Relative VEGFR-1 CPG methylation.  Following treatment with 
bisulphite, VEGFR-1 methylation was assessed by methylation-specific polymerase 
chain reaction (MSP).  * indicates p<0.05. 
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Summary 
This work makes several contributions to the current understanding of 
resistance to AVA therapy, with important clinical implications.  
 
1)  Increases in tumoral macrophages are associated with the emergence of 
resistance to AVA therapy.  The depletion of macrophages at this transition point 
restores sensitivity to AVA therapy and prolongs survival in murine models.  The 
upfront combination of bisphosphonates with AVA therapy is synergistic in reducing 
tumor growth. 
 
2)  Prolonged AVA therapy induces adaptive changes in macrophages, with 
upregulation of angiogenic and anti-apoptotic pathways, which may facilitate tumor 
growth in the AVA resistant microenvironment. 
 
3)  AVA therapy results in downregulation of macrophage VEGFR-1.  This 
decreased expression of macrophage VEGFR-1 is secondary to increased VEGFR-
1 promoter methylation.    
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Discussion 
Biological significance of macrophages in anti-VEGF resistance 
 While macrophages have been previously implicated in the development 
resistance to chemotherapy, their role in resistance to VEGF blockade is not well 
studied (59, 84).  Previously, targeting of the Ang/Tie2 pathway has impaired the 
angiogenic activity of Tie2 expressing macrophages and diminished the emergence 
of resistance in vivo (62).  In our detailed investigation into the contribution of 
macrophages to anti-VEGF resistance, we first show decreased TAM infiltration in 
tumors sensitive to AVA therapy.  This mirrors previously published data showing 
that AVA therapy can decrease tumoral macrophages (85).  Next, we demonstrate, 
for the first time, chronological increases in tumoral macrophages with the 
emergence of resistance to anti-VEGF therapy.   
 This influx of macrophages has important biological significance, as 
macrophages are capable of secreting numerous angiogenic factors, including 
VEGF, PlGF, and others seen in Table 1(86).  Indeed, in coordination with elevated 
macrophage counts, we show dramatically increased blood vessel density in AVA 
resistant tumors. The significance of macrophages in AVA resistance is most 
dramatically illustrated by the prolonged survival of mice receiving zoledronic acid 
following the emergence of resistance.   As compared to mice receiving only AVA 
therapy, who all developed resistance and quickly became moribund, those mice 
receiving zoledronic acid had stable or reduced disease burden and lived for up to 
six months following tumor cell injection.  We also show the potential additive 
combination of bisphosphonate with AVA therapy in the upfront setting.  While mice 
51 
 
in all groups were sacrificed when the control groups became moribund, those 
receiving AVA therapy with bisphosphonates demonstrated no evidence resistance 
and had very little disease burden.   
 Several other experiments need to be performed to definitely prove the 
catalytic role of macrophages in AVA resistance.  First, we are presently creating a 
murine Csf1 knockout model.  Homozygous mice lack Csf1, a critical growth factor 
for development of the monocyte and macrophage lineage, resulting in a dramatic 
reduction of systemic macrophage counts (87).  Csf1op/ Csf1op mice will be injected 
intraperitoneally with IG10 cells and assigned to 1) no treatment, or 2) AVA alone. 
Matched groups of wild-type C57Bl/6 will also be injected with IG10 cells to serve as 
additional controls.    As compared to wild-type mice, we expect Csf1op/ Csf1op mice 
receiving no treatment to have a prolonged disease course, while those receiving 
AVA will fail to develop resistance to VEGF blockade.   
We will also investigate whether re-introduction of macrophages into our 
Csf1 knockout model will restore the wild-type pattern of AVA resistance.  Csf1op/ 
Csf1op knockout mice will be injected with IG10 cells and assigned to 1) AVA 
therapy alone, or 2) AVA therapy plus macrophage transfusion. Matched groups of 
wild-type C57Bl/6 will be injected with IG10 cells to serve as controls.  We predict 
the survival of Csf1op/ Csf1op receiving macrophage infusion therapy with AVA 
therapy to recapitulate that of untreated wild-type mice.  Untreated Csf1op/ Csf1op 
mice should fail to develop resistance to AVA therapy. 
 In light of recent data suggesting that both resident and bone marrow-derived 
macrophages can proliferate, the origin of influxing macrophages must be 
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delineated (54). We are currently investigating whether the increase in 
macrophages seen at the emergence of resistance is secondary to resident 
macrophage proliferation or increased recruitment from bone marrow populations. 
In this experiment, bone marrow was isolated from GFP-labeled FVB.Cg-Tg(CAG-
EGFP)B5Nagy/J mice.  These mice express a GFP label in all tissues, including the 
bone marrow and its derived cells. Following cell sorting to confirm GFP labeling, 
harvested bone marrow cells were injected into irradiated wild-type C57Bl/6 mice 
(n=15).  Successful bone marrow transplant will be confirmed by hematologic 
profiling 4 weeks post-transplant, including verification of GFP expression in bone 
marrow-derived cells.  Recipient mice will then be injected with luciferase-labeled 
IG10 cells and tumor establishment verified 21 days after injection.  Mice will 
receive AVA therapy twice weekly in conjunction with weekly bioluminescent 
imaging. Mice will be while sensitive and resistant to VEGF blockade, as 
demonstrated by imaging.  Macrophages of bone marrow origin will be GFP-
labeled, while resident tissue macrophages will not be labeled, allowing them to be 
distinguished.  Injection with BRDU prior to sacrifice will allow us to determine if the 
increase in macrophages with AVA resistance is secondary to proliferation.   
Mechanisms 
In this study, we prove that AVA sensitive and resistant macrophages are 
phenotypically distinct.  AVA resistant macrophages display increased cell viability 
and increased migratory ability, as compared to their AVA sensitive counterparts.  
Additionally, AVA resistant macrophages have altered cytokine secretion, with 
significantly increased production of PDGF-AA and decreased VEGF.  PDGF-AA is 
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implicated in both the autocrine and paracrine angiogenic switch in solid tumors 
(88).  To our knowledge, this is the first time a distinctly different macrophage 
population has been shown to emerge in response to AVA therapy.  
Additionally, we use high-throughput studies to show that pro-angiogenic and 
anti-apoptotic pathways are upregulated in AVA resistant macrophages.  While 
many studies have focused on tumor cell adaptation to AVA therapy, this is the first 
to specifically show macrophage adaptation to AVA therapy.  Collectively, we 
believe these changes allow macrophages to continue to aid tumor growth in the 
face of AVA therapy, where they might otherwise be depleted.  
We demonstrate modulation of macrophage VEGFR-1 in response to AVA 
therapy. The reduction in expression of macrophage VEGFR-1 is secondary to 
increased VEGFR-1 promoter methylation.  Promoter methylation is a known 
mechanism for drug resistance (89, 90). We are currently exposing AVA resistant 
macrophages to the de-methylating agent, azacitidine. Restoration of AVA 
sensitivity would support VEGFR-1 methylation as a mechanism of drug resistance 
in macrophages. 
Macrophage VEGFR-1 expression has also been linked to phenotypic 
behavior, as antibody blockade of VEGFR-1 reduces monocyte and macrophage 
VEGF-induced migration (91, 92). It is possible that macrophage VEGFR-1 is 
downregulated in response to an AVA therapy-induced reduction of VEGF levels in 
the microenvironment.   
Other potential explanations for decreased macrophage VEGFR-1 exist.  Our 
observed effect could be in response to hypoxia, which is known to be induced by 
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AVA therapy (93).  Previous data from our laboratory shows that AVA therapy leads 
to hypoxia and increased EZH2 expression (94).  EZH2 decreases vasohibin 1 
(VASH1), leading to increased angiogenesis.  Data not published in our original 
study also demonstrates a reduction in VEGFR-1 in response to increased EZH2 
levels.  We currently have several experiments underway to determine if hypoxia 
alone can downregulate macrophage VEGFR-1.  Together these experiments will 
elucidate the complete mechanisms responsible for the VEGFR-1 reduction 
described in this work.  
Clinical implications 
Our study has important clinical implications.  We show depletion of 
macrophages at the emergence of anti-VEGF resistance using bisphosphonates 
can halt tumor growth and prolong survival in murine models. Additionally, the 
combination of bisphosphonates plus anti-VEGF therapy can prevent the 
development of resistance and improve the effectiveness of anti-angiogenic 
therapy.   
These findings offer direct support to previous clinical observations regarding 
the tumor-modifying ability of bisphosphonates, which have been shown to reduce 
bone metastasis in breast cancer patients, and in those with prostate or renal cell 
carcinoma and pre-existing bone metastasis, result in a trend towards increased 
survival (64, 66).  As further evidence, we investigated the effects of 
bisphosphonate use on overall cancer mortality using the Federal Drug 
Administration (FDA) Adverse Event Reporting System. Of approximately 17,000 
patients with a cancer diagnosis co-medicated with a bisphosphonate, overall 
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reported death rate was 36% lower (17.6% vs 27.7%, p<0.0001) than those not 
receiving bisphosphonates, seen below in Figure 23.   Additionally, we are in the 
process of obtaining IRB approval to investigate outcomes of cancer patients 
receiving bisphosphonates at M.D. Anderson Cancer Center. 
 
Figure 22. Overall mortality in cancer patients co-medicated with 
bisphosphonates.   Using the FDA Adverse Event Reporting System, 191,387 
cancer patients who did not receive bisphosphonates and 16,952 patients co-
medicated with a bisphosphonate were identified.  Overall mortality is shown above 
as a percentage as a percentage of each group.  *** indicates p<0.0001. 
 
Given the role of macrophages in resistance to VEGF blockade, strategies to 
modify macrophage response should be investigated in combination with anti-VEGF 
therapy in patients.  Possible approaches include bisphosphonates, as described 
here, CSF-1 inhibitors, CCR2 inhibitors, and trabectedin (67, 70, 71). Consideration 
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should be given to the upfront combination of these therapies with VEGF blockade, 
thereby diminishing the opportunity of macrophages to contribute to anti-VEGF 
resistance.  Our group is in the preliminary stages of trial design to investigate the 
use of bisphosphonates or a CSF-1 inhibitor, AC708 (Ambit Biosciences; San 
Diego, CA), in patients initially responsive to bevacizumab.  A detailed treatment 
schema is seen below in Figure 24. 
Figure 23.  Proposed trial design to investigate macrophage depletion in 
combination with bevacizumab.  Patients initially responsive to bevacizumab will 
be randomized to receive either a bisphosphonate or a CSF-1 inhibitor, AC708.   
 
Additionally, we are investigating macrophage VEGFR-1 expression as a 
potential as a predictor of response to AVA therapy.  We have obtain human 
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ovarian cancer samples from patients treated with bevacizumb and are currently 
performing inmmunohistochemical staining to assess  VEGFR-1 expression in 
macrophages.  We will then retrospectively correlate this with patients’ response to 
bevacizumab treatment.  We predict that patients with low macrophage VEGFR-1 
expression will have diminished bevacizumab efficacy compared to those with high 
macrophage VEFR-1 expression. 
Limitations and Conclusions 
In the current study, we demonstrate the previously unrecognized role of 
macrophages in resistance to VEGF blockade.  We show that macrophage 
accumulation in the tumor microenvironment correlates with the emergence of anti-
VEGF resistance.  The downregulation of VEGFR-1 is seen in conjunction with 
upregulation of alternative angiogenic and anti-apoptotic pathways, facilitating 
escape from VEGF-directed therapies.   
While the evidence presented in this study offers new insights into AVA 
resistance, more work remains to be done to clearly elucidate the mechanisms 
behind our observations.  Further, bisphosphonates are known to have effects not 
specific to macrophages, including decreasing endothelial cell migration and 
cytokine secretion (article in press; Reusser N, et al, Clodronate Inhibits Tumor 
Angiogenesis in Mouse Models of Ovarian Cancer, Cancer Biology & Therapy).  As 
such, the addition of a more specific method of macrophage depletion, such as a 
CSF-1 inhibitor, would strengthen the evidence presented here.  The use of only a 
bisphosphonate at the emergence of AVA resistance, instead of AVA plus a 
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bisphosphonate, should serve as an additional control and is being incorporated 
into our future experiments. 
In summary, we describe the previously unrecognized role of macrophages 
in resistance to anti-VEGF therapy.  We offer strategies to modulate the influence of 
macrophages, thus improving the effectiveness of VEGF blockage.  These readily 
translatable findings warrant further clinical investigation. 
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